<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05038098</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0410</org_study_id>
    <secondary_id>NCI-2021-08919</secondary_id>
    <secondary_id>2021-0410</secondary_id>
    <nct_id>NCT05038098</nct_id>
  </id_info>
  <brief_title>Magnetic Sentinel Lymph Node Mapping in Gastric Cancer</brief_title>
  <official_title>Magnetic Sentinel Lymph Node Mapping in Gastric Cancer, Safety and Feasibility Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I finds out the possible benefits and/or side effects of using magnetic tracer&#xD;
      FerroTrace and the fluorescent dye indocyanine green to identify the lymph nodes that cancer&#xD;
      is most likely to have spread to in patients with gastric cancer that are undergoing&#xD;
      gastrectomy. Using FerroTrace in combination with the indocyanine green dye may help&#xD;
      researchers better detect the disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To assess safety by assessing short term toxicity associated with the gastric injection of&#xD;
      the novel magnetic tracer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the feasibility of sentinel lymph node (SLN) imaging and mapping using novel&#xD;
      magnetic nanoparticles (iron conjugated polymers in saline suspension [FerroTrace]) for&#xD;
      gastric cancer, and to determine whether pre-operative injection, intra-operative injection,&#xD;
      or both are feasible.&#xD;
&#xD;
      II. To test the validity of this procedure by correlating sentinel lymph nodes (SLN) to&#xD;
      predict pathologic Lymph node (LN)-positive status i.e., will a negative SLN accurately&#xD;
      predict the negativity of the other LNs? III. To determine the diagnostic value of additional&#xD;
      hematoxylin and eosin (H&amp;E) sections and immunohistochemistry to assess sentinel lymph nodes&#xD;
      compared to routine assessment with one H&amp;E stain alone.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 of 2 cohorts.&#xD;
&#xD;
      COHORT I (PREOPERATIVE INJECTION): Patients receive FerroTrace peritumorally within days&#xD;
      1-21. Patients then undergo gastrectomy and receive indocyanine green (ICG) peritumorally.&#xD;
&#xD;
      COHORT II (INTRAOPERATIVE INJECTION): Patients undergo gastrectomy and receive FerroTrace and&#xD;
      ICG peritumorally during surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 13, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of endoscopic peritumoral gastric injection of FerroTrace</measure>
    <time_frame>Within 24 hours of the FerroTrace injection</time_frame>
    <description>The Bayesian method by Thall et al. will be applied for interim toxicity monitoring. Toxicities are defined as any grade III or greater toxicities attributable to FerroTrace injection, which occur within 24 hours of the injection. Will summarize the rate of adverse events (AEs) in all patients and by cohort, along with the exact 95% confidence interval.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort I (preoperative injection)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive FerroTrace peritumorally within days 1-21. Patients then undergo gastrectomy and receive ICG peritumorally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort II (intraoperative)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo gastrectomy and receive FerroTrace and ICG peritumorally during surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastrectomy</intervention_name>
    <description>Undergo surgery</description>
    <arm_group_label>Cohort I (preoperative injection)</arm_group_label>
    <arm_group_label>Cohort II (intraoperative)</arm_group_label>
    <other_name>Gastric Resection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine Green</intervention_name>
    <description>Given peritumorally</description>
    <arm_group_label>Cohort I (preoperative injection)</arm_group_label>
    <arm_group_label>Cohort II (intraoperative)</arm_group_label>
    <other_name>ICG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Iron Conjugated Polymers in Saline Suspension</intervention_name>
    <description>Given peritumorally</description>
    <arm_group_label>Cohort I (preoperative injection)</arm_group_label>
    <arm_group_label>Cohort II (intraoperative)</arm_group_label>
    <other_name>FerroTrace</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
          -  Willing to provide informed consent&#xD;
&#xD;
          -  Biopsy proven gastric cancer, undergoing curative-intent gastrectomy&#xD;
&#xD;
          -  No distant metastases&#xD;
&#xD;
          -  Pathologic diagnosis of gastric adenocarcinoma&#xD;
&#xD;
          -  Pre-treatment endoscopic measurement of less than or equal to 4 cm in diameter of the&#xD;
             gastric cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to surgery +/- adjuvant therapy&#xD;
&#xD;
          -  Allergy or intolerance to iron oxide compounds&#xD;
&#xD;
          -  Allergy or intolerance to iodides&#xD;
&#xD;
          -  Iron overload disorder&#xD;
&#xD;
          -  Pregnant or lactating women*&#xD;
&#xD;
               -  Use of contraception is required for females during the study. Male patients who&#xD;
                  are sexually active with a female of childbearing potential are allowed for study&#xD;
                  enrollment and will not require use of contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naruhiko Ikoma</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naruhiko Ikoma</last_name>
      <phone>713-792-6940</phone>
      <email>nikoma@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Naruhiko Ikoma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

